To evaluate the long-term efficacy and safety of bimekizumab in patients with moderate to severe plaque psoriasis over a 3-year period.
Key Findings:
At week 4, bimekizumab showed higher rates of symptom resolution compared to secukinumab: no itching (34% vs 25.1%), no skin pain (74.5% vs 60%), no scaling (46.1% vs 21.6%).
At year 1, the rates improved for bimekizumab: no itching (60.9% vs 48.1%), no skin pain (78.6% vs 70.8%), no scaling (70.5% vs 49.7%).
At year 3, concurrent achievement of PASI score of 0 and DLQI score of 0 or 1 was reported in 62.2% of continuous bimekizumab patients and 63.8% of those who switched from secukinumab.
Interpretation:
Bimekizumab demonstrated rapid and sustained improvements in psoriasis symptoms and health-related quality of life over 3 years.
Limitations:
Eligibility criteria may limit generalizability to broader patient populations.
